Work

A plain language summary of the MIRACLE study: benralizumab in people in Asia with severe asthma

Year: 2025

Type: article

Abstract: Plain Language SummaryWhat is this summary about?This summary describes the results of the Phase 3 MIRACLE study, originally published in the Respiratory Medicine journal. MIRACLE was the first clinical trial to evaluate the efficacy and safety of benralizumab injections in a large group of people from Asia with severe asthma.What were the main results of the MIRACLE study?People with severe asthma who took benralizumab had fewer asthma attacks (also called exacerbations). They also had better lung function, fewer asthma symptoms, better symptom control, and better health-related quality of life. The improvements in lung function and symptom control began as early as 4 weeks after the first benralizumab dose. A similar percentage of people in the benralizumab and placebo groups had adverse events.What do the results of MIRACLE mean?The MIRACLE results support the use of benralizumab as a treatment option for people in Asia with severe eosinophilic asthma. Benralizumab shows potential to improve asthma control and health-related quality of life in this population.This is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-text

Source: Immunotherapy

DOI: 10.1080/1750743x.2025.2550237